Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $4.25 million. The enterprise value is $12.72 million.
Important Dates
The next estimated earnings date is Tuesday, December 9, 2025, before market open.
| Earnings Date | Dec 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 1.55 million shares outstanding.
| Current Share Class | 1.55M |
| Shares Outstanding | 1.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +162.05% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 1.47% |
| Float | 1.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 1.48.
| Current Ratio | 0.07 |
| Quick Ratio | 0.03 |
| Debt / Equity | 1.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.61% |
| Return on Invested Capital (ROIC) | -557.92% |
| Return on Capital Employed (ROCE) | -84.21% |
| Revenue Per Employee | $265,392 |
| Profits Per Employee | -$8.88M |
| Employee Count | 5 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | -974,381 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.67% in the last 52 weeks. The beta is 3.42, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.42 |
| 52-Week Price Change | -98.67% |
| 50-Day Moving Average | 3.23 |
| 200-Day Moving Average | 10.19 |
| Relative Strength Index (RSI) | 36.28 |
| Average Volume (20 Days) | 28,125 |
Short Selling Information
The latest short interest is 123,432, so 7.96% of the outstanding shares have been sold short.
| Short Interest | 123,432 |
| Short Previous Month | 108,880 |
| Short % of Shares Out | 7.96% |
| Short % of Float | 9.91% |
| Short Ratio (days to cover) | 0.48 |
Income Statement
In the last 12 months, Onconetix had revenue of $1.33 million and -$44.39 million in losses. Loss per share was -$197.20.
| Revenue | 1.33M |
| Gross Profit | 881,717 |
| Operating Income | -5.41M |
| Pretax Income | -45.16M |
| Net Income | -44.39M |
| EBITDA | -5.08M |
| EBIT | -5.41M |
| Loss Per Share | -$197.20 |
Full Income Statement Balance Sheet
The company has $283,515 in cash and $8.75 million in debt, giving a net cash position of -$8.47 million or -$5.46 per share.
| Cash & Cash Equivalents | 283,515 |
| Total Debt | 8.75M |
| Net Cash | -8.47M |
| Net Cash Per Share | -$5.46 |
| Equity (Book Value) | 5.91M |
| Book Value Per Share | 5.86 |
| Working Capital | -11.76M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$5.47 million and capital expenditures -$6,187, giving a free cash flow of -$5.48 million.
| Operating Cash Flow | -5.47M |
| Capital Expenditures | -6,187 |
| Free Cash Flow | -5.48M |
| FCF Per Share | -$3.54 |
Full Cash Flow Statement Margins
| Gross Margin | 66.45% |
| Operating Margin | -407.86% |
| Pretax Margin | -3,403.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onconetix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,045.13% |
| FCF Yield | -129.03% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 13, 2025. It was a reverse split with a ratio of 1:85.
| Last Split Date | Jun 13, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:85 |
Scores
Onconetix has an Altman Z-Score of -10.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.6 |
| Piotroski F-Score | 3 |